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Abstract
Background: The Metabolic Syndrome (MetS) is a cluster of metabolic abnormalities that includes hyperglucemia,
hypertension, dyslipidemia and central obesity, conferring an increased risk of cardiovascular disease. The white blood cell
(WBC) count has been proposed as a marker for predicting cardiovascular risk. However, few prospective studies have
evaluated the relationship between WBC subtypes and risk of MetS.
Methods: Participants were recruited from seven PREDIMED study centers. Both a baseline cross-sectional (n = 4,377) and a
prospective assessment (n = 1,637) were performed. Participants with MetS at baseline were excluded from the longitudinal
analysis. The median follow-up was 3.9 years. Anthropometric measurements, blood pressure, fasting glucose, lipid profile
and WBC counts were assessed at baseline and yearly during the follow-up. Participants were categorized by baseline WBC
and its subtype count quartiles. Adjusted logistic regression models were fitted to assess the risk of MetS and its
components.
Results: Of the 4,377 participants, 62.6% had MetS at baseline. Compared to the participants in the lowest baseline sex-
adjusted quartile of WBC counts, those in the upper quartile showed an increased risk of having MetS (OR, 2.47; 95%CI,
2.03–2.99; P-trend,0.001). This association was also observed for all WBC subtypes, except for basophils. Compared to
participants in the lowest quartile, those in the top quartile of leukocyte, neutrophil and lymphocyte count had an increased
risk of MetS incidence. Leukocyte and neutrophil count were found to be strongly associated with the MetS components
hypertriglyceridemia and low HDL-cholesterol. Likewise, lymphocyte counts were found to be associated with the incidence
of the MetS components low HDL-cholesterol and high fasting glucose. An increase in the total WBC during the follow-up
was also associated with an increased risk of MetS.
Conclusions: Total WBC counts, and some subtypes, were positively associated with MetS as well as hypertriglyceridemia,
low HDL-cholesterol and high fasting glucose, all components of MetS.
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Introduction
In recent years, the prevalence of metabolic syndrome (MetS)
has increased dramatically in both developed and developing
countries. MetS is a constellation of cardiovascular risk factors
(impaired glucose tolerance, hypertension, dyslipidemia and
central obesity) strongly associated with type 2 diabetes, cardio-
vascular diseases, and other chronic conditions, all of which
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increase the risk of mortality [1,2]. Thus, early identification of the
subjects who are at high risk of developing MetS may help prevent
associated cardiovascular events.
The peripheral circulating white blood cell (WBC) count is an
objective marker of acute infection, tissue damage, and other
inflammatory conditions. Moderately high levels of leukocyte
counts have been positively associated with type 2 diabetes [3,4]
and the progression or severity of atherosclerosis [5,6]. Thus, the
leukocyte count has been proposed as an emerging biomarker for
predicting future cardiovascular events [7,8] and mortality [9].
The assessment of the association between the WBC count and the
development of the MetS may help to a better understanding of
the pathophysiology of the MetS because chronic subclinical
inflammation has been implicated in the genesis of MetS, [10,11]
and the leukocyte count may be seen as an inflammation marker
that is related to this condition. In fact, for over a decade cross-
sectional studies have been showing that there is a close
relationship between WBC and MetS prevalence, mainly in Asian
populations [4,12–20]. Considerably less research, however, has
explored the associations between MetS or its features and
different subtypes of leukocyte [14–19,21].
The prospective studies that have examined the relationship
between WBC count and the risk of MetS are limited and
controversial. To the best of our knowledge, only two studies have
explored these associations. One of them was a cohort of
preadolescents, adolescents and young adults that longitudinally
analyzed the association between WBC count and MetS incidence
in white individuals [22]. Recently, an increase was also observed
in the MetS incidence across WBC count quartiles in a cohort of
workers followed for 7 years, [23] but adiposity indexes were not
taken into account when this association was explored. Beyond
these two studies, the associations between leukocyte subtype
count and MetS (or its components) have never been explored
prospectively.
Therefore, the aim of the present study was to evaluate total
leukocyte count and subtype count as possible predictors of the
development of MetS and/or its features in a population at high
risk of cardiovascular disease.
Methods
Design and population
The PREDIMED (Prevención con DIeta MEDiterránea) Study
is a large, parallel-group, multicenter, randomized, controlled
clinical trial that aims to assess the effects of the Mediterranean
Diet (MedDiet) on the primary prevention of cardiovascular
disease (http://www.predimed.es; http://www.predimed.org).
The design, methodology and eligibility criteria for the PRE-
DIMED study have been previously described [24,25]. Briefly,
7,447 community-dwelling men (aged 55–80 years) and women
(aged 60–80 years) with no previously documented cardiovascular
disease were recruited. They were eligible if they had type 2
diabetes, or three or more of the following cardiovascular risk
factors: hypertension, high plasma LDL-cholesterol, low plasma
HDL-cholesterol, overweight or obesity, current smoking, or a
family history of premature coronary heart disease. Participants
were randomized to three intervention groups (two of which were
advised to follow a MedDiet (MedDiet) supplemented with either
virgin olive oil or nuts, and one of which was advised to follow a
low-fat diet).
In the present study, we cross-sectionally and longitudinally
analyzed the associations between WBC counts and the presence
and development of MetS and its components in a subset of 4,377
participants recruited in seven PREDIMED centers where
information about WBC count was collected (Navarra, Málaga,
Barcelona-North, Vitoria, Sevilla, Gran Canaria, and Reus). No
significant differences were found for the main baseline variables
(age, sex and BMI) between PREDIMED participants included or
not included in the present analysis. Only those participants free of
MetS at baseline were included in the longitudinal analysis. In the
longitudinal analysis, we used as exposure the baseline leukocyte
count (or the leukocyte subtypes). The main outcome was the
incidence of the MetS during any assessment along all the follow-
up period, expanding up to 7 years (median follow-up: 3.9 years).
Therefore any new case of MetS occurring in any time point
during the follow-up period among subjects initially free of the
MetS was considered as an incident event.
Ethics statement
All participants provided informed consent. The Institutional
Review Board (IRB) of the Hospital Clinic (Barcelona, Spain)
accredited by the US Department of Health and Human Services
(DHHS) update for Federal wide Assurance for the Protection of
Human Subjects for International (Non-US) Institutions #
00000738 approved the study protocol on July, 16, 2002. The
protocol was also approved by the respective institutional ethical
review boards.
Outcomes
MetS was defined in accordance with the updated harmonized
criteria of the International Diabetes Federation and the American
Heart Association/National Heart, Lung, and Blood Institute
[26]. That is to say subjects were regarded as having MetS when
they had three or more of the following components:
- Elevated waist circumference for European individuals
($88 cm and $102 cm in women and men, respectively).
- Elevated triglycerides [150 mg/dL (1.7 mmol/L)] or drug
treatment for elevated triglycerides.
- Low concentrations of high density lipoprotein cholesterol
(HDL-c) [40 mg/dL (1.0 mmol/L) in men; 50 mg/dL
(1.3 mmol/L) in women] or drug treatment for low HDL-C.
- Elevated blood pressure (systolic $130 and/or diastolic
$85 mm Hg) or antihypertensive drug treatment.
- Elevated fasting glucose [$100 mg/dL (5.5 mmol/L)] or
drug treatment for elevated glucose.
Measurements
In a personal interview, participants completed: a) a question-
naire about lifestyle variables, medical history and medication use;
b) a 14-item validated questionnaire [27] designed to assess the
degree of adherence to the MedDiet; and, c) the validated Spanish
version [28] of the Minnesota Leisure-Time Physical Activity
Questionnaire. Trained personnel took anthropometric measure-
ments (weight, height and waist circumference) and blood pressure
was measured using a validated oscillometer [Omron
HEM705CP, Hoofddorp, Netherlands] in triplicate. These
questionnaires were administered and measurements were record-
ed at baseline and yearly during follow-up.
Biochemical determinations
Fasting plasma glucose, serum total cholesterol, HDL-choles-
terol and triglyceride concentrations were measured at baseline
and yearly, using standard enzymatic automated methods. LDL-
cholesterol was estimated by the Friedewald equation when the
direct parameter was not available. WBC and different leukocyte
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counts (neutrophil, lymphocyte, monocyte, basophils, and eosin-
ophil) were measured using an automated analyzer.
Statistical analyses
Continuous variables are presented as median and interquartile
range [IR] for non-normally distributed data. Data with skewed
distributions determined with the Kolmogorov-Smirnov test were
log-transformed before analysis.
Partial correlation coefficients adjusted for sex were used to
analyze the relationship between the total leukocyte count (or
subtypes) and each of the specific criteria for the MetS (abdominal
obesity, hypertriglyceridemia, low HDL-cholesterol levels, hyper-
tension, and high fasting plasma glucose concentrations).
To assess the risk of MetS for each category of WBC count in
cross-sectional analyses, participants were categorized according to
their baseline sex-adjusted WBC count quartiles. To prospectively
assess the risk of MetS or its components, new WBC count
quartiles were constructed for participants free of MetS at baseline.
Unadjusted and adjusted logistic regression models were fitted to
assess the associations between baseline quartiles of total WBC
count (or each leukocyte subtype) and the prevalence of MetS.
Logistic regression models were adjusted for the intervention
group (two dummy variables), baseline age (years), smoking (three
categories), leisure-time physical activity expressed in metabolic
equivalents (METs-min/d), MedDiet score (0–14 points), alcohol
consumption (g/day), BMI (kg/m2), and recruitment center.
Unadjusted and adjusted logistic regression models were also
fitted to longitudinally assess the above associations. In the
longitudinal analysis we also used as exposure the quartiles of
baseline WBC (or each leukocyte subtype count). The outcome
was the incidence of MetS (or each of the specific defining criteria).
In the adjusted models, the following potential confounders were
included as covariates: intervention group, baseline age, tobacco
use, physical activity, MedDiet score and alcohol consumption
(Model 1); the same confounders used in model 1 plus baseline
BMI and recruitment centre (Model 2), and the same confounders
used in previous models plus baseline features of the MetS
(dichotomous variables) [the fully-adjusted model]. To assess linear
trends in all logistic regression models we introduced the median
value of each quartile of the WBC count as a continuous variable
in the different models.
To estimate the change in the probability of the MetS being
diagnosed given that two years ago the leukocyte count differed by
a certain amount, we fitted generalized estimating equations with
robust standard errors, to estimate the odds ratio of being classified
as having the MetS given that two years ago the leukocyte count
differed by 2*109 cells/L (an amount close to the standard
deviation). We adjusted these estimates for the same confounders
as the main logistic regression model and thus obtained an outer
expectation for all the available time points, together with an inner
expectation for all possible values of the confounders.
We analyzed the area under the ROC curve to predict the
prevalence or the incidence of MetS with and without the variable
leukocyte count (or leukocyte subtypes). We compared ROC
curves using Stata 12.0’s roccomp command, which uses the
method suggested by DeLong, DeLong, and Clarke-Pearson [29].
Cox regression models were fitted to assess the relative risk of
MetS across total leukocyte, neutrophil and lymphocyte quartiles,
estimated with hazard ratios (HR) and 95% confidence intervals
(CI). The time variable used was the interval between the baseline
measurement date and the date of the last follow-up, death or
outcome diagnosis, whichever occurred first. Models were
adjusted for the same variables described for model 2.
A second longitudinal analysis was conducted to assess the
associations between changes in WBC count during follow-up and
the incidence of MetS. The participants were dichotomized in two
categories: a) those who remained in the same WBC count
(leukocyte, neutrophil and lymphocyte) quartiles (2nd, 3rd, or 4th)
or who switched to a higher quartile during the follow-up; and b)
those who remained in the 1st quartile or switched to a lower
quartile during the follow-up.
Two-tailed P-values ,0.05 were considered significant. Statis-
tical analyses were done with the SPSS (version 19.0, SPSSInc,
Chicago, IL).
Results
Table 1 classifies the participants according to their baseline
WBC count (quartiles). Of the 4,377 participants, 62.6%
(n = 2,740) met the criteria for MetS at baseline. For waist
circumference the criteria for MetS were met in 72%, for
hypertriglyceridemia in 33%, for low HDL-c in 27%, for elevated
blood pressure in 94.4%, and for elevated fasting glucose
components of the MetS in 64.6%.
Participants with MetS had higher peripheral leukocyte counts
(median 6.5, IR [5.5–7.7] cells x109/L) than those without MetS
(6.0 [5.1–7.0]; P ,0.001). Mean body-mass-index, waist circum-
ference, blood pressure, and fasting glucose and triglyceride
concentrations were significantly higher in the upper quartiles
than in the lowest (reference). The percentage of participants with
MetS or each of the defining criteria for the MetS was significantly
higher across successively increasing WBC count quartiles.
After adjusting for sex, low but significant direct correlations
were found between log-transformed leukocyte, neutrophil or
lymphocyte counts and plasma glucose (0.116, 0.117 and 0.042,
respectively), triglycerides (0.178, 0.131 and 0.177, respectively),
and waist circumference (0.094, 0.93 and 0.034, respectively).
Conversely, significant inverse correlations were observed between
the cell counts and log-transformed HDL-c concentrations
(–0.144, –0.135 and –0.084, respectively).
In the cross-sectional baseline analysis, participants in the upper
quartile of total leukocyte count had a greater prevalence of MetS
than participants in the lowest quartile (OR, 2.47; 95% CI, 2.03–
2.99; P for trend ,0.001). This significant association was also
observed for the neutrophil count (OR, 2.09; 95% CI, 1.73–2.54;
P for trend ,0.001), lymphocytes (OR, 1.56; 95% CI, 1.29–1.88;
P for trend ,0.001), monocytes (OR, 1.41; 95% CI, 1.16–1.72; P
for trend ,0.001), and eosinophils (OR, 1.43; 95% CI, 1.18–1.72;
P for trend ,0.001) (Table 2). These associations remained
significant even after participants with WBC count $11.0 cells x
109/L (n = 83, 1.9% of the total sample) were excluded.
Of the 4,377 participants, 1,637 did not meet the MetS criteria
at baseline. For 16 of them, enough data were available to
diagnose metS at baseline. Thus, longitudinal analyses were
carried out in a sample of 1,621 individuals (546, 532 and 523
participants randomized to a MedDiet supplemented with virgin
olive oil, a MedDiet supplemented with nuts, and a low-fat control
diet, respectively). The retention rates for $ 2 years follow-up were
98.9%, 98.5% and 96.8%, respectively) (see figure 1.)
Over the 7-year study period, with a median follow-up of 3.9
[2.0–5.8] years, 726 (350 men and 376 women) of the 1,621
participants free of MetS at baseline developed new-onset MetS
(cumulative incidence: 44.8%, 95% CI 42.4–47.2). Participants
who developed MetS had significantly higher WBC counts at
baseline than those who did not (6.1 [5.1–7.3] cells x 109/L vs. 5.9
[5.0–7.0] cells x 109/L, P = 0.003). The incidence of MetS was
significantly higher across leukocyte and neutrophil quartiles, and
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PLOS ONE | www.plosone.org 3 March 2013 | Volume 8 | Issue 3 | e58354
of borderline statistical significance across lymphocyte quartiles (P
= 0.072).
Table 3 shows the logistic regression analyses that explore the
associations between total leukocytes or other subtypes of WBC
count and incidence of MetS. Compared to subjects in the lowest
quartile, subjects in the highest quartile of leukocyte, neutrophil
and lymphocyte counts had an increased risk of MetS incidence.
In the fully-adjusted model these associations remained significant
for neutrophil counts, and were of borderline significance for total
leukocytes (P = 0.065) and lymphocytes (P = 0.090). Considering
that there was a difference in the leukocyte count of 2*109 cells/L
two years before the MetS was assessed, the estimates for the Odds
Ratio (OR) obtained using generalized estimating equations with
robust standard errors (Appendix S1) were 1.20 (95%CI, 1.08–
1.34) in the multivariable adjusted model (P = 0.001), and 1.17
(95%CI, 1.05–1.31) in the additionally adjusted model for baseline
criteria for MetS. The Hosmer-Lemeshow test of the multivariable
adjusted logistic regression model using leukocyte quartiles as
predictors of the incidence of MetS during follow-up showed a
reasonable goodness of fit (P = 0.81). The results were very similar
when individuals (n = 24) with increased leukocyte counts
(.11*109 cells/L) were excluded from the analysis (Appendix
S1). The area under the ROC curve was only slightly higher
(AUC = 0.609) when the total leukocyte count was used than with
the basic model (AUC = 0.603). There was no significant
difference between them (P = 0.29).
Cox regression showed that participants in the highest quartile
of leukocyte and neutrophil counts showed a significantly high risk
of MetS than those in the lowest quartile (Hazard ratio [HR] for
total leukocyte count 1.34 [95% CI, 1.08–1.66], PQ4 vs Q1 = 0.009;
HR for neutrophil count 1.39 [95% CI, 1.13–1.72], PQ4 vs Q1
= 0.002). No significant association was observed between the
lymphocyte count and the risk of MetS (data not shown).
Table 4 shows the incidence of each of the specific MetS
defining criteria in subjects initially free of the respective
component for each of the total leukocyte, neutrophil and
lymphocyte count quartiles. The incidence of hypertriglyceridemia
and low HDL-cholesterol increased significantly across leukocyte
count quartiles.
Participants initially free of hypertriglyceridemia at baseline and
who were in the upper quartile of leukocyte, neutrophil and
lymphocyte counts had a significantly higher risk of developing the
hypertriglyceridemia criteria of the MetS during the follow-up
even after adjusting for all potential confounders.
Participants free of the MetS low-HDL cholesterol criteria at
baseline and who were in the upper quartile of the total leukocyte
and neutrophil counts also had a significantly higher risk of
developing this MetS component during the follow-up even after
adjusting for all confounders.
For high fasting plasma glucose the same positive association
was shown across leukocyte and lymphocyte quartiles, but the
association across neutrophil quartiles was not statistically
significant (P = 0.121).
Table 1. Baseline characteristics of participants across sex-adjusted leukocyte count quartiles (first to fourth: Q1 to Q4).
Q1 Q2 Q3 Q4 P-valuea
Participants, n 1085 1113 1069 1110
Leukocyte counts, cells x 109/L - median [percentile 25th–75th] 4.74 [4.30–5.06] 5.84 [5.60–6.10] 6.90 [6.60–7.15] 8.50 [7.90–9.40] NA
Age, years - mean 6 SD 67.2 6 6.1 67.1 6 6.1 67.1 6 6.2 66.9 6 6.3 0.711
Sex,
Women, % (n) 57.1 (619) 55.7 (620) 57.7 (617) 56.3 (625) NA
Body Mass Index, kg/m2 - mean 6 SD 29.5 6 3.7 29.9 6 3.5 30.1 6 3.7 30.3 6 3.9 ,0.001
Waist circumference, cm - mean 6 SD 98.6 (10.1) 99.5 (10.4) 100.4 (10.0) 101.1 (10.2) ,0.001
Current smoker, % (n) 7.8 (85) 11.1 (124) 15.2 (163) 24.1 (268) ,0.001
Former smoker, % (n) 24.1 (262) 27.9 (310) 25.4 (271) 23.2 (257) 0.064
Physical activity, METs - mean 6 SD 263 6 267 246 6 242 247 6 267 218 6 225 , 0.001
Mediterranean diet score, 0 to 14 points - mean 6 SD 8.8 6 1.9 8.7 6 2.0 8.7 6 1.9 8.6 6 1.9 0.052
Systolic blood pressure, mmHg - mean 6 SD 147.6 6 19.3 148.9 6 20.2 150.0 6 20.5 151.4 6 20.9 ,0.001
Diastolic blood pressure, mmHg - mean 6 SD 82.4 6 10.9 83.2 610.5 83.1 6 10.4 83.8 6 11.1 0.026
Fasting plasma glucose, mg/dL - mean 6 SD 114.0 6 35.7 120.0 6 40.7 124.0 6 42.0 127.1 6 45.8 ,0.001
Triglycerides, mg/dL [percentile 25th-75th] 104.0 [77.0–142.0] 120.0 [88.0–163.0] 124.5 [94.0–168.0] 132.0 [100.0–178.7] ,0.001
HDL-cholesterol, mg/dL [percentile 25th–75th] 55.0 [47.0–67.0] 53.0 [45.0–62.9] 52.0 [44.0–62.0] 59.0 [43.0–59.0] ,0.001
Prevalence of type 2 diabetes mellitus, % (n) 40.1 (435) 44.0 (490) 51.2 (547) 52.0 (577) ,0.001
Metabolic syndrome and prevalence of its components
Metabolic syndrome, % (n) 51.7 (561) 60.1 (669) 65.7 (702) 71.8 (808) ,0.001
Abdominal obesity, % (n) 68.6 (737) 71.7 (791) 74.9 (796) 74.9 (828) 0.002
Hypertriglyceridemia, % (n) 24.1 (261) 32.9 (365) 34.6 (369) 40.5 (448) ,0.001
Low HDL-cholesterol level, % (n) 21.2 (229) 25.8 (286) 28.6 (305) 32.9 (362) ,0.001
Hypertension, % (n) 93.5 (1015) 94.0 (1045) 94.0 (1005) 96.3 (1067) 0.020
High fasting plasma glucose concentrations, % (n) 56.8 (616) 63.0 (701) 67.4 (720) 71.2 (790) ,0.001
aANOVA for continuous variables and x2 for categorical variables test were used for comparisons across the total leucocyte count quartiles.
doi:10.1371/journal.pone.0058354.t001
White Blood Cell Counts and Metabolic Syndrome
PLOS ONE | www.plosone.org 4 March 2013 | Volume 8 | Issue 3 | e58354
Finally, those participants who remained in the same WBC
count quartiles (2nd, 3rd, or 4th) or switched to a higher quartile
during the follow-up had a 32% higher risk of developing MetS
than those participants who remained in the 1st quartile or
switched to a lower quartile during the follow-up (Table 5). This
association remained significant even after additionally adjusting
for baseline MetS features, and changes in total body weight or
MedDiet adherence during the follow-up (data not shown).
Discussion
The present study is the first longitudinal assessment to have
investigated the relationship between WBC counts or leukocyte
subtype counts and the risk of developing MetS or some of its
components in a large population sample at high cardiovascular
risk. Our longitudinal assessment shows that total WBC and WBC
subtype counts are directly and significantly associated with the
incidence of MetS and some of its specific defining criteria. An
increase in the WBC count during the follow-up was also related
to a higher risk of MetS.
Our cross-sectional results are consistent with reported associ-
ations between WBC and the prevalence of MetS [18,19]. These
associations have been observed in small [14,15,30,31] and large
population samples [12,18,19], in preadolescent, adolescent and
young individuals [20,22], in healthy adults [4,12,19], in the
elderly [30,31], and in individuals with type 2 diabetes [5,15,17].
Very few of these previous cross-sectional studies have analysed
the associations between WBC subtype counts and MetS. An
association between total leukocyte, neutrophil and lymphocyte
count and the prevalence of MetS has been observed in an elderly
Chinese population [19]. This association has also been observed
for total leukocyte counts and subtype counts (neutrophils,
lymphocytes, monocytes, basophils and eosinophils) in a cross-
sectional study of Korean individuals [18]. More recently, high
circulating lymphocyte sub-population counts have been associat-
ed with an increased prevalence of MetS [21]. In our study, with
the exception of basophils, all WBC subtype counts were
associated with a higher prevalence of MetS.
Only two prospective studies [22,23] have analysed the
relationship between the total WBC count and the MetS (or each
of its defining criteria), and both showed a direct association.
However, the associations between WBC subtype counts and the
incidence of MetS or its components was not specifically explored
in either of these studies. The first study was conducted in a
Japanese population, included 5,043 workers initially free of MetS
(mean age: 42.5 years), and was followed for 7 years [23]. A total
of 925 participants were newly diagnosed with MetS during
follow-up. The adjusted hazard ratio for the highest versus the
lowest quartile of the WBC count was 1.67 (95% CI: 1.36-2.05).








n = 1110 P for trend
Total leukocytes
Cells x 109/L- median [percentile 25th–75th] 4.74 [4.30–5.06] 5.84 [5.60–6.10] 6.90 [6.60–7.15] 8.50 [7.90–9.40] NA
Unadjusted 1 1.41 (1.19–1.67) 1.79 (1.50–2.13) 2.29 (1.91–2.73) , 0.001
Adjusteda 1 1.35 (1.12–1.61) 1.70 (1.42–2.05) 2.47 (2.03–2.99) , 0.001
Neutrophils
Cells x 109/L- median [percentile 25th–75th] 2.53 [2.20–2.89] 3.22 [2.86–3.60] 3.90 [3.52–4.34] 5.12 [4.43–5.90] NA
Unadjusted 1 1.23 (1.03–1.45) 1.65 (1.39–1.96) 2.21 (1.85–2.64) , 0.001
Adjusteda 1 1.22 (1.02–1.47) 1.66 (1.38–2.00) 2.09 (1.73–2.54) , 0.001
Lymphocytes
Cells x 109/L- median [percentile 25th–75th] 1.54 [1.32–1.81] 1.95 [1.66–2.27] 2.19 [1.82–2.53] 2.55 [2.09–3.07] NA
Unadjusted 1 1.20 (1.01–1.43) 1.44 (1.21–1.71) 1.59 (1.34–1.89) , 0.001
Adjusteda 1 1.10 (0.92–1.33) 1.41 (1.17–1.70) 1.56 (1.29–1.88) , 0.001
Monocytes
Cells x 109/L- median [percentile 25th–75th] 0.34 [0.27–0.42] 0.42 [0.34–0.50] 0.48 [0.38–0.58] 0.59 [0.46–0.71] NA
Unadjusted 1 1.17 (0.98–1.39) 1.16 (0.97–1.37) 1.37 (1.15–1.63) 0.001
Adjusteda 1 1.22 (1.01–1.47) 1.20 (0.99–1.46) 1.41 (1.16–1.72) 0.002
Eosinophils
Cells x 109/L- median [percentile 25th–75th] 0.12 [0.08–0.17] 0.15 [0.10–0.21] 0.18 [0.12–0.25] 0.21 [0.14–0.30] NA
Unadjusted 1 1.31 (1.10–1.56) 1.46 (1.23–1.74) 1.46 (1.23–1.74) , 0.001
Adjusteda 1 1.33 (1.11–1.60) 1.43 (1.19–1.72) 1.43 (1.18–1.72) , 0.001
Basophils
Cells x 109/L- median [percentile 25th–75th] 0.03 [0.02–0.04] 0.03 [0.02–0.04] 0.04 [0.02–0.05] 0.04 [0.03–0.06] NA
Unadjusted 1 1.02 (0.86–1.22) 0.93 (0.78–1.10) 1.11 (0.93–1.32) 0.470
Adjusteda 1 1.06 (0.88–1.27) 0.95 (0.79–1.14) 1.10 (0.91–1.32) 0.571
Odds ratios (95% confidence intervals) with the lowest quartile as the reference category.
aLogistic regression models adjusted for intervention group, and baseline age, BMI, tobacco use, physical activity, Mediterranean diet score, alcohol consumption and
study centre; NA: Not applicable.
doi:10.1371/journal.pone.0058354.t002
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The association between WBC subtypes and MetS incidence was
not specifically assessed. The second study (Bogalusa cohort) was
conducted in children and young adults, and it showed that there
was a racial difference (the association was present in whites but
not in blacks) in the correlations between WBC counts and each of
the specific parameters used as defining criteria for the MetS [22].
Figure 1. Flowchart of study participants. Abbreviations: MedDiet = Mediterranean diet; MetS = Metabolic syndrome; WBC = white blood cell.
doi:10.1371/journal.pone.0058354.g001
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In our study we demonstrated that the total WBC and some cell
subtype counts were associated with an increased risk of MetS (and
some of the defining criteria for the MetS), but we were not able to
explore racial differences because the study population consisted
almost exclusively of Europeans. We found that WBC counts were
also positively associated with three of the parameters used as
defining criteria for the MetS: hyperglycemia, low HDL-choles-
terol, and hypertriglyceridemia.
The positive association observed in our study between the total
leukocyte, neutrophil and lymphocyte counts and the hyperglyce-
mia component was supported by a meta-analysis of 20 cross-
sectional and prospective cohort studies exploring the association
between WBC counts and type 2 diabetes [5]. The biological
mechanisms explaining these associations remain to be elucidated.
It seems very likely that a low-grade systemic inflammation
associated with obesity and insulin resistance precedes and predicts
the development of diabetes. Adipocytes, especially in obese
subjects, secrete a number of proinflammatory cytokines, [32]
some of which have been shown to directly inhibit insulin
signalling [33]. Adipocytokines probably act through master
proinflammatory regulators such as those of the nuclear factor-
kB and the c-Jun NH2-terminal kinase (JNK)/AP-1 signalling
pathways [34] to modulate the expression of gene coding for many
inflammatory proteins and to alter insulin signalling.
The prospective association observed in our study between the
total and subtype WBC counts and hypertriglyceridemia or low-
HDL cholesterol components of MetS is in agreement with
previous cross-sectional studies and the prospective assessment in
the Bogalusa cohort. This can also be explained through
inflammation. Early cross-sectional studies conducted in hyperlip-
idemic patients revealed that an increase in the total peripheral
leukocyte count and subtype counts (except for eosinophils) was
mainly associated with higher serum triglyceride concentrations
and hypertriglyceridemia [35]. Other epidemiological studies have
also reported a positive association between WBC count (or some
subtype counts) and hypertriglyceridemia or low-HDL cholesterol
concentrations [35,36]. An association between total lymphocyte
counts and hypertriglyceridemia or low-HDL cholesterol has also
recently been reported only in men [36].
Lipid metabolism disorders found during inflammation are the
result of increased triglyceride concentrations and decreased
HDL-cholesterol levels (two components of the so-called athero-
genic dyslipidemia). Inflammation and atherogenic dyslipidemia
may be linked by the fact that TNF alpha and IL-6 stimulate
lipolysis and increase the flow of free fatty acids to the liver. This
increase in free fatty acids induces hepatic triglyceride synthesis
and increases very low density lipoprotein secretion from the liver,
both of which increase hepatic triglyceride production and
secretion, thus causing hypertriglyceridemia [37]. TNF alpha
and IL-6 also suppress lipoprotein lipase synthesis in adipose
tissue, which may contribute to hypertriglyceridemia and the low
HDL-cholesterol concentrations observed in individuals with
intra-abdominal obesity [38].
Some authors have hypothesized that a high WBC count causes
a low-grade chronic inflammation that impairs endothelial
function. This affects the production of nitric oxide and
prostacyclin and results in hypertension and the loss of vasodilator
capacity [39]. In our study, the lack of association between the
Table 3. Incidence of new cases of metabolic syndrome during the follow-up among subjects initially free of metabolic syndrome








n = 399 P-value
Total leukocytes
Metabolic syndrome incidence, % 39.0 45.1 45.0 50.0 0.020a
Unadjusted 1 1.29 (0.97–1.70) 1.28 (0.97–1.69) 1.56 (1.18–2.07) 0.003b
Adjusted model 1c 1 1.28 (0.97–1.69) 1.26 (0.95–1.67) 1.54 (1.15–2.05) 0.006b
Adjusted model 2d 1 1.22 (0.92–1.63) 1.22 (0.92–1.62) 1.53 (1.12–2.02) 0.009b
Fully-adjusted modele 1 1.19 (0.88–1.59) 1.14 (0.85–1.53) 1.37 (1.01–1.86) 0.062b
Neutrophils
Metabolic syndrome incidence, % 41.4 40.5 44.4 57.7 0.005a
Unadjusted 1 0.97 (0.73–1.28) 1.13 (0.86–1.50) 1.52 (1.15–2.01) ,0.001b
Adjusted model1c 1 0.95 (0.85–1.48) 1.12 (0.85–1.48) 1.49 (1.12–2.00) 0.001b
Adjusted model 2d 1 0.97 (0.73–1.29) 1.12 (0.84–1.49) 1.47 (1.09–1.96) 0.002b
Fully-adjusted modele 1 0.89 (0.66–1.20) 1.04 (0.77–1.39) 1.32 (0.98–1.80) 0.004b
Lymphocytes
Metabolic syndrome incidence, % 40.6 41.9 48.3 47.1 0.072a
Unadjusted 1 1.06 (0.80–1.40) 1.37 (1.03–1.81) 1.30 (0.99–1.73) 0.025b
Adjusted model 1c 1 1.05 (0.79–1.43) 1.36 (1.03–1.81) 1.27 (0.96–1.69) 0.043b
Adjusted model 2d 1 1.02 (0.77–1.36) 1.31 (0.99–1.75) 1.29 (0.96–1.72) 0.039b
Fully-adjusted modele 1 1.05 (0.78–1.42) 1.28 (0.95––1.72) 1.24 (0.91–1.67) 0.106b
Odds ratios (95% confidence intervals).
aP-value by x2 test.
bP for trend.
cLogistic regression model adjusted for intervention group, and baseline age, tobacco use, physical activity, Mediterranean diet score and alcohol consumption.
dLogistic regression models adjusted for variables used in model 1 plus baseline BMI and recruitment centre.
eLogistic regression models adjusted for variables used in model 2 plus baseline features of the metabolic syndrome.
doi:10.1371/journal.pone.0058354.t003
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Table 4. Incidence of each metabolic syndrome component among subjects initially free of its respective component according to
baseline sex–adjusted leukocyte counts. Odds ratios (95% confidence intervals).
Q1 Q2 Q3 Q4 P-value
High fasting plasma glucose
Leukocyte
Participants, n 371 383 365 368
High fasting plasma glucose incidence, % 37.3 38.3 36.5 36.8 0.066a
Unadjusted 1 0.96 (0.71–1.30) 1.28 (0.95–1.71) 1.33 (0.99–1.71) 0.017b
Adjusted model 1c 1 0.95 (0.70–1.28) 1.24 (0.92–1.68) 1.30 (0.96–1.77) 0.033b
Adjusted model 2d 1 0.91 (0.67–1.24) 1.20 (0.88–1.02) 1.25 (0.92–1.71) 0.058b
Neutrophils
Unadjusted 1 0.94 (0.70–1.27) 1.32 (0.98–1.77) 1.18 (0.88–1.59) 0.058b
Adjusted model 1c 1 0.93 (0.69–1.26) 1.29 (0.96–1.74) 1.14 (0.84–1.55) 0.085b
Adjusted model 2d 1 0.95 (0.70–1.29) 1.33 (0.98–1.80) 1.16 (0.85–1.58) 0.121b
Lymphocytes
Unadjusted 1 0.93 (0.69–1.26) 1.47 (1.09–1.98) 1.45(1.07–1.95) 0.001b
Adjusted model 1c 1 0.92 (0.68–1.25) 1.43 (1.06–1.94) 1.40 (1.03–2.90) 0.003b
Adjusted model 2d 1 0.90 (0.66–1.23) 1.38 (1.02–1.87) 1.34 (0.99–1.82) 0.009b
Hypertriglyceridemia
Leukocyte
Participants, n 742 734 745 730
Hypertriglyceridemia incidence, % 25.9 28.7 31.0 35.1 0.001a
Unadjusted 1 1.15 (0.92–1.45) 1.29 (1.03–1.62) 1.55 (1.24–1.94) ,0.001b
Adjusted model 1c 1 1.23 (0.92–1.46) 1.28 (1.02–1.61) 1.52 (1.21–1.91) ,0.001b
Adjusted model 2d 1 1.21 (0.90–1.43) 1.25 (1.00–1.58) 1.48 (1.17–1.86) 0.001b
Neutrophils
Unadjusted 1 1.18 (0.93–1.48) 1.28 (1.02–1.61) 1.45 (1.16–1.82) 0.001b
Adjusted model 1c 1 1.17 (0.93–1.48) 1.29 (1.02–1.62) 1.43 (1.14–1.81) 0.002b
Adjusted model 2d 1 1.19 (0.95–1.50) 1.46 (1.16–1.84) 1.48 (1.17–1.88) 0.002b
Lymphocytes
Unadjusted 1 1.07 (0.85–1.36) 1.33 (1.06–1.67) 1.46 (1.16–1.84) ,0.001b
Adjusted model 1c 1 1.06 (0.84–1.34) 1.29 (1.02–1.62) 1.39 (1.12–1.74) 0.001b
Adjusted model 2d 1 1.02 (0.80–1.29) 1.21 (0.96–1.53) 1.33 (1.05–1.67) 0.006b
Low HDL-cholesterol
Leukocyte
Participants, n 825 756 820 795
Low-HDL cholesterol incidence, % 21.8 27.3 27.5 32.3 ,0.001a
Unadjusted 1 1.35 (1.07–1.70) 1.36 (1.08–1.71) 1.71 (1.37–2.14) , 0.001b
Adjusted model 1c 1 1.36 (1.08–1.72) 1.38 (1.10–1.73) 1.79 (1.42–2.25) , 0.001b
Adjusted model 2d 1 1.35 (1.08–1.71) 1.36 (1.08–1.71) 1.74 (1.39–2.19) , 0.001b
Neutrophils
Unadjusted 1 1.09 (0.86–1.38) 1.57 (1.25–1.97) 1.72 (1.37–2.16) ,0.001b
Adjusted model 1c 1 1.10 (0.87–1.40) 1.60 (1.27–2.01) 1.79 (1.42–2.25) ,0.001b
Adjusted model 2d 1 1.10 (0.87–1.40) 1.57 (1.25–1.98) 1.74 (1.39–2.19) ,0.001b
Lymphocytes
Unadjusted 1 1.09 (0.82–1.29) 1.06 (0.85–1.33) 1.06 (0.85–1.33) 0.559b
Adjusted model 1c 1 1.03 (0.85–1.34) 1.07 (0.84–1.33) 1.06 (0.84–1.33) 0.581b
Adjusted model 2d 1 1.03 (0.82–1.29) 1.07 (0.85–1.34) 1.06 (0.84–1.30) 0.583b
High blood pressure
Leukocyte
Participants, n 58 61 63 61
White Blood Cell Counts and Metabolic Syndrome
PLOS ONE | www.plosone.org 8 March 2013 | Volume 8 | Issue 3 | e58354
leukocyte count and high blood pressure may be explained by the
fact that more than 90% of our study participants were
hypertensive, thus making it difficult to explore these associations.
The current study has some limitations. First, the high
prevalence of cardiovascular risk factors among our participants
may limit the generalizability of our findings to general
populations or younger adults. However, this high prevalence
may even increase the interest of the association reported. It is well
known that the wider the between-subject variability in a
biomarker, the easier it is to find associations between that
biomarker and the outcome. The homogeneity of the high
cardiovascular risk of the PREDIMED participants probably
decreases the likelihood of finding strong associations with factors
potentially associated with the characteristics of the MetS, because
the between-subject variability is lower than in a representative
sample of the general population. Therefore, the fact that we have
found an association between leukocyte counts and MetS even in
our suboptimal scenario may be seen as support for that
association. Second, we did not exclude from the analysis those
participants with a recognized chronic inflammatory disease,
which may influence the WBC count. However, we did explore all
these associations before or after excluding participants with a
WBC count $11.06109 cells/L, and the results remained
essentially the same (Appendix S1). Third, we admit that the true
statistical model relating the measured variables cannot really be
known and standard logistic regression and other similar models
have been defined only as ‘‘simplified pictures of reality’’ [40].
However, we believe that the use of this simplified approach has
become familiar to the scientific community because it is the
standard approach in epidemiology. Fourth, the inclusion of WBC
values increased the area under the ROC curve only slightly and
non-significantly. Finally, the prospective component was only a
modest proportion of the total trial, which may lead to selection
bias.
Conclusions
Total and subtype WBC counts were directly and significantly
associated with the incidence of MetS and also with the
hypertriglyceridemia, low HDL-cholesterol and high fasting
plasma glucose components of the MetS. WBC counts can be
regarded as markers of an increased production of cytokines and
Table 4. Cont.
Q1 Q2 Q3 Q4 P-value
High blood pressure incidence, % 78.9 78.3 79.4 71.7 0.718a
Unadjusted 1 0.96 (0.40–2.33) 1.03 (0.43–2.48) 0.89 (0.33–2.39) 0.415b
Adjusted model 1c 1 1.16 (0.46–2.93) 1.13 (0.45–2.84) 0.80 (0.32–1.96) 0.621b
Adjusted model 2d 1 0.83 (0.47–3.04) 1.09 (0.43–2.76) 0.81 (0.33–2.02) 0.625b
Neutrophils
Unadjusted 1 0.42 (0.17–1.03) 0.47 (0.18–1.19) 0.79 (0.30–2.06) 0.696b
Adjusted model 1c 1 0.40 (0.16–1.05) 0.48 (0.19–1.22) 0.83 (0.30–2.28) 0.789b
Adjusted model 2d 1 0.39 (0.15–1.02) 0.90 (0.37–3.19) 0.87 (0.30–2.45) 0.900b
Lymphocytes
Unadjusted 1 0.94 (0.39–2.28) 0.90 (0.37–3.19) 0.66 (0.28–1.54) 0.347b
Adjusted model 1c 1 1.00 (0.40–2.49) 1.15 (0.45–2.90) 0.76 (0.32–1.85) 0.642b
Adjusted model 2d 1 0.93 (0.37–2.36) 1.08 (0.42–2.79) 0.67 (0.27–1.68) 0.487b
Abdominal obesity
Leukocyte
Participants, n 302 294 303 300
Abdominal obesity incidence, % 37.3 40.7 36.6 39.5 0.716a
Unadjusted 1 1.15 (0.82–1.60) 0.97 (0.69–1.35) 1.10 (0.79–1.53) 0.844b
Adjusted model 1c 1 1.15 (0.83–1.62) 0.99 (0.66–1.39) 1.18 (0.84–1.66) 0.782b
Adjusted model 2d 1 1.08 (0.76–1.54) 1.02 (0.67–1.46) 1.20 (0.84–1.73) 0.398b
Neutrophils
Unadjusted 1 0.89 (0.64–1.24) 0.82 (0.58–1.14) 1.01 (0.73–1.41) 0.932b
Adjusted model 1c 1 0.89 (0.64–1.26) 0.91(0.57– 1.14) 1.02 (0.72–1.45) 0.956b
Adjusted model 2d 1 1.00 (0.66–1.35) 0.90 (0.63–1.29) 1.13 (0.79–1.62) 0.594b
Lymphocytes
Unadjusted 1 1.21 (0.87–1.69) 1.19 (0.85–1.66) 0.98 (0.70–1.37) 0.855b
Adjusted model 1c 1 1.26 (0.87–1.77) 1.25 (0.89–1.76) 1.03 (0.72–1.35) 0.882b
Adjusted model 2d 1 1.22 (0.81–1.74) 1.17 (0.82–1.67) 0.93 (0.65–1.35) 0.669b
aP-value = x2 test; b P for trend; c Logistic regression models adjusted for intervention group, and baseline variables: age, current and former smoker, physical activity,
Mediterranean diet score and alcohol; d Logistic regression model adjusted for model 1 plus baseline BMI and recruitment node.
doi:10.1371/journal.pone.0058354.t004
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acute-phase reactants, and the activation of the inflammatory
signalling network involved in the pathogenesis of insulin
resistance and atherogenic dyslipidemia, the main metabolic
disorders underlying MetS [41].
Supporting Information
Appendix S1 Odds Ratios for the MetS according to the
leukocyte count measured 2 years previously.
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